{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001178879","name":"AMICUS THERAPEUTICS, INC.","summary":"Amicus Therapeutics is a global biotechnology company focused on rare diseases. It markets two therapies: Galafold (migalastat), an oral monotherapy approved in 40+ countries for Fabry disease, and Pombiliti + Opfolda (cipaglucosidase alfa-atga/miglustat), a two-component treatment for adult late-onset Pompe disease approved in multiple countries. The company is also developing DMX-200 for FSGS and has entered a merger agreement with BioMarin Pharmaceutical.","people":[],"products":[{"name":"Galafold (migalastat)","type":"platform","description":"Oral small molecule pharmacological chaperone for Fabry disease patients with amenable GLA variants; approved in 40+ countries."},{"name":"Pombiliti + Opfolda (cipaglucosidase alfa-atga/miglustat)","type":"platform","description":"Two-component intravenous and oral treatment for adult late-onset Pompe disease; approved in U.S., E.U., U.K., Canada, Australia, Switzerland, and Japan."},{"name":"DMX-200","type":"platform","description":"Small molecule CCR2 inhibitor in Phase 3 (ACTION3) for Focal Segmental Glomerulosclerosis (FSGS); licensed from Dimerix for U.S. commercialization."}],"partnerships":[{"partner_name":"Dimerix Bioscience Pty Limited","partnership_type":"licensing","description":"Exclusive license agreement for U.S. commercialization rights of DMX-200 for FSGS and other indications, signed April 30, 2025.","start_date":null},{"partner_name":"BioMarin Pharmaceutical Inc.","partnership_type":"strategic","description":"Definitive merger agreement signed December 19, 2025; BioMarin to acquire Amicus at $14.50 per share; expected to close Q2 2026.","start_date":null}],"affiliations":[],"origin":{"leaf":"4eeeb41025da5585c1b08d7393cdd67ef33a77cbbc03fb6207f427ae94f94a19","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f6dc9e88e5160e44150971935e19a52419af796e7fb8ee009c519e74451798f8","parent":"44ff280aef79ee9a1ff4afa7283e387559bb018d18e848ac4c62bd2d1e9d5c11","source":"0001178879-26-000005","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}